New eye drops aim to slow diabetic vision damage
NCT ID NCT07198815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests NPDR-01 eye drops in 10 adults with non-proliferative diabetic retinopathy, a common eye complication of diabetes. Participants will use one drop daily for 6 months to see if it reduces tiny retinal bleeds (microaneurysms) and slows disease progression. The goal is to find a simple, non-invasive treatment to protect vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NPDR-01 eye drops
- What this could lead to
- If it works, this could point toward a simple eye drop treatment to slow vision loss from diabetic retinopathy.
- What could go wrong
- This is a very early, tiny trial with only 10 people. It may not show clear benefit, and the drops might not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINAL MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI eye doctor: could software catch diabetic blindness sooner?
- Can eye scans reveal hidden clues about diabetes damage?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling
- Eye scans could spot Diabetes-Related vision damage years early